What we know so far: COVID-19 current clinical knowledge and research

Author: Mary A Lake

In December 2019, health authorities in Wuhan, China, identified a cluster of pneumonia cases of unknown aetiology linked to the city’s South China Seafood Market. Subsequent investigations revealed a novel coronavirus, SARS-CoV-2, as the causative agent now at the heart of a major outbreak. The rising case numbers have been accompanied by unprecedented public health action, including the wholesale isolation of Wuhan. Alongside this has been a robust scientific response, including early publication of the pathogen genome, and rapid development of highly specific diagnostics. This article will review the new knowledge of SARS-CoV-2 COVID-19 acute respiratory disease, and summarise its clinical features.

KEYWORDS: 2019-nCoV, coronavirus, Wuhan, respiratory tract infection, SARS-CoV-2

DOI: 10.7861/clinmed.2019-coron

Introduction

Over the course of December 2019 in the city of Wuhan in Hubei province, Chinese health authorities identified a cluster of pneumonia cases of unknown aetiology. Features included pyrexia, radiological signs or acute respiratory distress, reduced or normal white blood cells, lymphopenia, and failure to resolve over 3 to 5 days of antibiotic treatment. Links between the index cases and the city’s South China Seafood Market were noted. With the possibility of a new zoonosis or severe acute respiratory syndrome (SARS) outbreak in mind, investigations were undertaken that have since identified a novel coronavirus, SARS-CoV-2 (formerly 2019-nCoV), as the agent now at the heart of an international outbreak centred around Hubei. Despite dramatic headlines in the international press, the outbreak has been characterised by an extraordinarily rapid and effective scientific response, with identification of the pathogen, publication of its genome, and development of highly specific diagnostics within weeks of the initial case detection.

This article will aim to provide a brief review of current knowledge of the COVID-19 acute respiratory disease, and summarise relevant clinical features as currently reported.

SARS-CoV-2

The clinical disease termed COVID-19 is caused by a novel betacoronavirus, now named SARS-CoV-2. SARS-CoV-2 shares 79% sequence identity with SARS-CoV, the virus which caused a major outbreak in 2002–2003. In common with SARS-CoV, SARS-CoV-2 utilises the ACE-2 receptor for cell entry. Electron microscopy reveals pleomorphic spherical particles, studded with distinctive spike proteins. Coronaviruses, a family which also includes Middle East respiratory syndrome (MERS) CoV and four of the main agents of the common cold, are zoonotic pathogens. In keeping with this, the first cluster of cases were identified in association with the South China Seafood Market, a ‘wet’ market at which a large range of live or freshly slaughtered animals were sold including poultry, bats, and snakes. A very early report suggesting a snake host for SARS-CoV-2, such as the Chinese cobra, garnered lurid news headlines but a cold scientific reception. This report used a technique which exploits the concept that amino acids can be coded for by more than one three-nucleotide sequence, and that different species have preferences for particular codon sequences. These data have since been superseded by more conventional phylogenetic analyses, and SARS-CoV-2 is currently thought to originate from a bat host, based on 88–96% sequence similarity to bat coronaviruses, in keeping with other pathogenic coronaviruses such as SARS-CoV and MERS-CoV. However, definitive identification of the animal host depends on detection of virus in situ in an infected animal. Additionally, another intermediate animal host more commonly in close contact with humans may also have played a role in Wuhan; SARS-CoV for example is thought to have passed from bats to humans via Himalayan palm civets, Chinese ferret badgers and raccoon dogs sold at the wet markets of Guangdong.

COVID-19 clinical presentation and management

Clinical features

The most common symptoms being reported are fever, cough or chest tightness, and dyspnoea. Most cases are reported to experience a mild illness course. Data regarding the relative frequency of severe illness is likely to be skewed at present by detection bias towards these cases; with sicker patients more likely to present for clinical assessment; these cases may therefore be over-represented in recent data.

Within the subset of patients admitted to hospital, a detailed clinical picture comes from a case series of 41 inpatients with
laboratory-confirmed COVID-19 disease. In this cohort, the median age of patients was 49 years (interquartile range (IQR) 41.0–58.0). The most common symptoms at onset of illness were fever (98%), cough (76%), dyspnoea (55%) and myalgia or fatigue (44%). Notably, few patients had prominent upper respiratory tract symptoms such as coryza and only one patient had diarrhoea. Other clinical features included sputum production (28%), headache (8%) and, in two cases, haemoptysis. The median time from onset of symptoms to first hospital admission was 7.0 days (IQR 4.0–8.0). Thirty-two per cent required intensive treatment unit (ITU) admission for respiratory support ranging from high-flow nasal cannula to invasive ventilation. Seventy-three per cent of patients were male and 32% had pre-existing comorbidities such as diabetes (20%), hypertension (15%) and cardiovascular disease (15%).

Laboratory features in this case series commonly included leukopenia (25%), lymphopenia (25%) and raised aspartate aminotransferase (37%, including seven of 28 non-ITU patients). ITU patients had raised prothrombin and D-dimer levels on admission relative to non-ICU patients. A raised troponin (hypersensitive-troponin I (hs-cTnI)) was detected in five patients, possibly suggestive of virus-associated myocardial injury. Abnormalities on computed tomography (CT) of the chest were seen in all patients, although the indication for imaging was not specified. Ninety-eight per cent had bilateral involvement, with ground-glass opacity and subsegmental areas of consolidation commonly seen. Complications included acute respiratory distress syndrome (29%) and secondary infection (10%). A follow-up study from the same centre which included these patients and a further 58 cases, found an overall mortality rate of 11% with 23% of patients requiring ITU admission, with a preponderance of older males with comorbidities. Half of patients were directly associated with the seafood market, including 47 sales people or market managers. In an epidemiological study of the first 425 cases in Wuhan, almost half were in adults of 60 years older but, importantly, the case definition at the time specified severe enough illness to require medical attention, thereby potentially missing milder presentations or biasing against younger patients with fewer comorbidities.

Initial assessment

COVID-19 is classified as an airborne high consequence infectious disease (HCID) in the UK. The cornerstone of management of all possible or confirmed cases is early triage and isolation. Assessments should be carefully prepared for, including in primary care where many patients are likely to present. During initial assessment, precautions should be taken to minimise transmission including, where possible, initial consultation by telephone. An action plan should be developed in healthcare areas where assessments are likely to occur. The key principles are to identify potential cases as soon as possible; prevent potential transmission of infection to other patients and staff; avoid direct physical contact including physical examination and exposures to respiratory secretions; and to isolate the patient. Practitioners should obtain specialist advice, determine if the patient is at risk of COVID-19, and inform the local health protection team.

Notably, if a history is elicited that suggests a possible case once consultation has already commenced, examination should be abandoned and the practitioner should leave the room, close the door, and wash their hands thoroughly with soap and water. The assessment can then be continued by telephone and the patient triaged appropriately and transfer arranged to an appropriate setting if indicated.

Clinicians are advised to check www.gov.uk/government/collections/wuhan-novel-coronavirus for the latest triage guidance. Prior to assessment of a patient identified as at risk of COVID-19, clinicians must isolate the patient with their belongings and waste in a single occupancy room, preferably a respiratory isolation room and ideally under negative pressure; positive pressure must not be used. Personal protective equipment (PPE) must be worn, comprising, as a minimum, a correctly fitted FFP3 respirator, gown, gloves and eye protection. Practitioners should be trained in the safe putting on and removal of PPE. Patients should be asked to wear a surgical facemask during transport to isolation. Patients are identified as possible cases by epidemiological and clinical criteria. An up-to-date case definition may be obtained from www.gov.uk/government/collections/wuhan-novel-coronavirus. Any further assessment, investigation and management should take place under strict infection control precautions and with close liaison with local infectious diseases and public health teams.

Diagnosis

Patients satisfying epidemiological and clinical criteria as specified at www.gov.uk/government/collections/wuhan-novel-coronavirus are classified as a possible case. If a patient meets the case definition, clinicians should consult the latest guidance from their public health authority. Diagnostic sampling must be undertaken only with appropriate infection control precautions and with discussion with local infectious diseases and public health teams. Testing of any samples should take place in a Biological Safety Level 3 laboratory. It is essential to inform the laboratory before sending samples. Early publication of the pathogen genome has allowed rapid development of a reverse transcription polymerase chain reaction (PCR) based test, and whole genome sequencing may also be carried out on positive samples to aid understanding of transmission and mutations. Point-of-care test kits are likely to be made available shortly for home testing. Serological markers have also been identified but are not currently useful for clinical diagnostics.

Specific clinical management

At present, there are no recommended antivirals for COVID-19 and management is as per best supportive care for any respiratory disease. Considerations for patients with severe acute respiratory illness include the early use of empirical antimicrobials and neuraminidase inhibitors to cover for alternative (or coexisting) diagnoses. A systematic review of interventions for the management of SARS-CoV patients found no definite benefits for ribavirin, with possible harm due to haemolytic anaemia and impaired liver function (raised alanine aminotransferase), while data on the combination of lopinavir 400 mg with ritonavir 100 mg orally every 12 hours was inconclusive due to study design, despite prior supportive in vitro findings. However, a randomised controlled trial of lopinavir/ritonavir for COVID-19 has already been initiated in Wuhan. There was no definite benefit for corticosteroids in SARS-CoV patients as a group, and some
studies found possible evidence of harm, such as delayed viral clearance, psychosis, diabetes and avascular necrosis. Evidence from management of MERS-CoV also suggests corticosteroids may delay viral clearance. However, other indications for corticosteroids such as exacerbation of asthma could potentially supervene. Remdesivir, a novel nucleotide analogue prodrug with activity against MERS-CoV in mouse models has been given to one COVID-19 patient in the USA on a compassionate basis without adverse events, and randomised controlled trials formally investigating its use in COVID-19 infection have already been registered.

Detailed guidance intended for the management of COVID-19 cases developing severe acute respiratory illness has been published by the World Health Organization (WHO) and is available online at www.who.int/emergencies/diseases/novel-coronavirus-2019; it is likely to be regularly updated and is therefore not reproduced here.

Transmission

Human-to-human transmission is now well established for COVID-19, with an R₀ (the expected number of secondary cases produced by a single (typical) infection in a completely susceptible population) currently estimated by the WHO as 1.4–2.5. For comparison, seasonal flu has a reported median R₀ of 1.28 (IQR 1.19–1.37), while measles has an R₀ usually reported as 12–18. However, an R₀ must be calculated from imperfect data and in different populations, and estimates are influenced by local variations in susceptibility, efficiency of case detection and infection control responses. Thus, the reported COVID-19 R₀ may change as further information becomes available.

Most human coronaviruses are transmitted mainly by the respiratory route or via contact with infected secretions. Samples from seven patients (six of whom were seafood peddlers or deliveryers at the wholesale market) with severe pneumonia in ITU early in the current outbreak were found to be positive for SARS-CoV-2 in six bronchoalveolar lavage fluid samples and five oral swabs by quantitative PCR and conventional PCR, supportive of a respiratory transmission route. Virus has also been detected in patient stool samples. Fomite spread via contaminated surfaces is also probable, based on SARS-CoV-2 transmission in mouse models. Nosocomial spread is also a significant concern.

The mean incubation period is brief, reported as 5.2 days, with the 95th percentile of the distribution at 12.5 days (95% confidence interval 9.2–18). One case documented an incubation period of just 3 days. Asymptomatic transmission of the virus was confirmed outside of China in 72 different countries.

Current outbreak status

As per the WHO situation report of 04 March 2020, the outbreak stands at 90,870 cases confirmed globally, with 10,566 cases confirmed outside of China in 72 different countries.

Conclusion

As novel pathogens have emerged and spread, the international response has become successively more sophisticated and far reaching. Initially detected by monitoring systems put in place after the SARS-CoV outbreak of 2002–2003, the emergence of SARS-CoV-2 has been accompanied by a remarkable response from public health bodies and the scientific community.

Additionally, major journals and publishers including The Lancet and Elsevier have responded to calls from the Wellcome Trust to make publications relevant to the outbreak immediately available free of charge, promoting wide dissemination of crucial early biological, epidemiological and clinical data.

Although the known severity of COVID-19 disease ranges from mild symptoms of upper respiratory tract infection (with or without fever) to severe pneumonia, most reported cases are at the mild end of the spectrum. At the time of writing, if COVID-19 infection is seen in the UK, it is most likely to occur in travellers that have recently returned from specified countries and areas; or had contact with a known case. Therefore, an accurate history including travel is a key component of risk identification.

Acknowledgements

Grateful thanks are due to Dr Colin Brown and Prof Clodina McNulty.
References


30 Kupferschmidt K. Study claiming new coronavirus can be transmitted by people without symptoms was flawed. Science, 2020.


Address for correspondence: Dr Alexandra Lake, Laboratory of Molecular Biology, Cambridge Biomedical Campus, Francis Crick Ave, Cambridge CB2 0QH, UK.
Email: alexandra.lake@doctors.org.uk